Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Pemetrexed and Carboplatin in Locally Advanced or Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2003-11-13
- Last Posted Date
- 2007-01-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 50
- Registration Number
- NCT00072865
- Locations
- 🇷🇺
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Saint Petersburg, Russia, Russian Federation
Duloxetine vs. Active Comparator in the Treatment of Patients With Depression
- Conditions
- First Posted Date
- 2003-10-30
- Last Posted Date
- 2007-05-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 320
- Registration Number
- NCT00071695
- Locations
- 🇫🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM - 5 PM Easter Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., La Rochelle, France
Duloxetine Compassionate Use in Patients Who Have Completed a Previous Neuroscience Duloxetine Clinical Trial
- First Posted Date
- 2003-10-30
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT00071708
- Locations
- 🇦🇺
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., West Perth, Western Australia, Australia
Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- First Posted Date
- 2003-10-16
- Last Posted Date
- 2007-01-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 48
- Registration Number
- NCT00071136
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY(1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC-GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States
A Study With Gemcitabine, Cisplatin, and LY293111 in Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2003-10-06
- Last Posted Date
- 2007-12-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 195
- Registration Number
- NCT00069875
- Locations
- 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician, Montreal, Quebec, Canada
🇪🇸For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Madrid, Spain
Duloxetine vs. Active Comparator for the Treatment of Depression
- Conditions
- First Posted Date
- 2003-09-03
- Last Posted Date
- 2007-05-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 480
- Registration Number
- NCT00067912
- Locations
- 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Calgary, Alberta, Canada
A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow Transplantation
- Conditions
- Interventions
- First Posted Date
- 2003-08-27
- Last Posted Date
- 2007-12-07
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 7
- Registration Number
- NCT00067730
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Winston-Salem, North Carolina, United States
Pemetrexed as First Line Chemotherapy for Advanced Breast Cancer
- Conditions
- First Posted Date
- 2003-07-29
- Last Posted Date
- 2007-06-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 92
- Registration Number
- NCT00065533
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hrs, EST), or speak with your personal physician., Birmingham, West Midlands, United Kingdom
An Evaluation of an Oral Antidiabetic Agent for the Treatment of Type 2 Diabetes
- Conditions
- First Posted Date
- 2003-07-22
- Last Posted Date
- 2006-07-19
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT00065312
- Locations
- 🇺🇸
For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559), Spokane, Washington, United States
Pemetrexed Plus Gemcitabine in Metastatic Breast Cancer Patients After Receiving Taxane Therapy
- Conditions
- Interventions
- First Posted Date
- 2003-07-01
- Last Posted Date
- 2009-05-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 73
- Registration Number
- NCT00063570
- Locations
- 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician., San Juan, Puerto Rico